328Tip Phase III Study of Trastuzumab Deruxtecan (T-Dxd) with or Without Pertuzumab Vs a Taxane, Trastuzumab and Pertuzumab in First-Line (1L), Human Epidermal Growth Factor Receptor 2–positive (HER2+) Metastatic Breast Cancer (mbc): DESTINY-Breast09
Annals of Oncology（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined